Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis

N

Nimble Science

Status

Enrolling

Conditions

Irritable Bowel Syndrome
Functional Dyspepsia
Celiac Disease
Ulcerative Colitis
Crohn Disease

Treatments

Device: fluid biopsy capsule

Study type

Observational

Funder types

Industry

Identifiers

NCT05633706
HREBA.CTC-22-0096

Details and patient eligibility

About

The SIMBA Capsule is a small, single-use, ingestible capsule that allows for the non-invasive sampling of small bowel contents using purely mechanical means. The study will compare the microbial and metabolomics analysis from the sample collected with the capsule series, to same-participant symptom questionnaires and stool microbial analysis.

Full description

The investigators primary goal is to assess the correlation of gut symptoms from various disease states with the dysbiosis of the small intestinal microbiome and metabolites collected by the SIMBA capsule, and as identified and measured by metagenomic sequencing and/or metabolomics approaches. The process consists of ingestion and collection of up to 4 SIMBA capsules, on up to 2 separate occasions, along with collection of a stool sample at the same time. Participants will also fill out a series of questionnaires on medical history and lifestyle inputs (eg. diet, exercise, mental health) GI symptoms, anxiety, and depression. The investigators ultimate goal will be to develop a better understanding of how the small intestinal microbiome might play a role in symptom generation, to establish whether the SIMBA capsule can find a signature of dysbiosis which can be used as a biomarker for a number of functional gut disorders.

Enrollment

150 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged between 18 and 80 years.
  • No previous diagnosis of Celiac Disease, Ulcerative Colitis, Crohn's disease, IBS, Functional Dyspepsia by participant self-report (Control group).
  • Prior diagnosis of Celiac Disease, Ulcerative Colitis, Crohn's disease, IBS, or Functional Dyspepsia by a relevant physician, nutritionist, naturopath, etc, and willingness to provide documentation to confirm this diagnosis or have a consultation with the PI. (Disease group).
  • Ability to understand and provide informed consent.
  • Ability and willingness to meet the required schedule, study interventions, and questionnaire requirements.
  • No planned change in diet or medical interventions during the study duration.

Exclusion criteria

  • Known disease which, in the investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion (particular diseases which would be assessed on a case-by-case basis would include, achalasia, eosinophilic esophagitis, cancer diagnosis or treatment within the past year, or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months prior to enrollment are acceptable). The main deciding factor would be a history of obstructive symptoms in the previous 3 months prior to entry.
  • Use of any medications or having undergone procedures in the previous week that could substantially alter gastrointestinal motor function (e.g., opioids, prokinetics, anticholinergics, laxatives), or acidity (PPI, H2RA) (Control Group only).
  • History of oropharyngeal dysphagia or other swallowing disorder with a risk of aspiration of the capsule.
  • Females of childbearing age who are pregnant or lactating by self-report. (should an X-ray be required for confirmation of capsule passage, a urine pregnancy test will be administered beforehand).
  • No antibiotics, or colon cleanses/bowel prep for 2 weeks.
  • < 2 bowel movements per week (Control Group only).

Trial design

150 participants in 6 patient groups

Healthy
Description:
Not belonging to the other cohorts as described below.
Treatment:
Device: fluid biopsy capsule
Irritable Bowel Syndrome
Description:
As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
Treatment:
Device: fluid biopsy capsule
Crohns Disease
Description:
As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
Treatment:
Device: fluid biopsy capsule
Ulcerative Colitis
Description:
As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
Treatment:
Device: fluid biopsy capsule
Celiac Disease
Description:
As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
Treatment:
Device: fluid biopsy capsule
Functional Dyspepsia
Description:
As confirmed by diagnosis and/or PI assessment, and measured via patient response to validated questionnaires - no interventions applied.
Treatment:
Device: fluid biopsy capsule

Trial contacts and locations

0

Loading...

Central trial contact

Joseph Wang, PhD; Sabina Bruehlmann, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems